MOORE CAPITAL MANAGEMENT, LP - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 116 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2021. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.

Quarter-by-quarter ownership
MOORE CAPITAL MANAGEMENT, LP ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2022$2,228,500
+164.4%
50,000
+66.7%
0.05%
+165.0%
Q3 2022$843,000
+76.0%
29,993
+68.7%
0.02%
+53.8%
Q2 2022$479,000
-21.0%
17,7810.0%0.01%
-13.3%
Q1 2022$606,000
-63.6%
17,781
-81.3%
0.02%
-16.7%
Q4 2020$1,664,00095,0000.02%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q1 2021
NameSharesValueWeighting ↓
ACUTA CAPITAL PARTNERS, LLC 1,017,524$20,961,0007.56%
Octagon Capital Advisors LP 561,398$11,565,0004.36%
COMMODORE CAPITAL LP 369,951$7,621,0003.04%
Opaleye Management Inc. 985,000$20,291,0002.98%
VR Adviser, LLC 1,240,610$25,557,0002.77%
TSP Capital Management Group, LLC 359,229$7,400,0002.61%
RTW INVESTMENTS, LP 3,908,947$80,524,0001.26%
Ghost Tree Capital, LLC 250,000$5,150,0001.21%
Tri Locum Partners LP 196,672$4,051,0001.00%
Redmile Group, LLC 3,387,788$69,788,0000.98%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders